Report of Foreign Issuer (6-k)
July 25 2016 - 1:03PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending 25 July 2016
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
GlaxoSmithKline plc (the
'
Company
')
Transaction notification
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Dr K Slaoui
|
b)
|
Position/status
|
PCA of Dr M M Slaoui (Chairman, Global Vaccines)
|
c)
|
Initial notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
a)
|
Description
of the financial
instrument
|
GlaxoSmithKline plc American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
b)
|
Nature of
the transaction
|
An increase of 1 ADS following the notional allocation of ADSs on 22 July 2016, at a price of $43.88 per ADS, as a result of the revaluation of the cash element of the notional investment held within the GSK 401(K) plan.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
$43.88
|
1
|
d)
|
Aggregated information
Aggregated volume Price
|
n/a (single transaction)
|
e)
|
Date of the transaction
|
2016-07-22
|
f)
|
Place of the transaction
|
n/a
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: July 25, 2016
By: VICTORIA WHYTE
----------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc
GSK (NYSE:GSK)
Historical Stock Chart
From Aug 2024 to Sep 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2023 to Sep 2024